Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1.
暂无分享,去创建一个
J. Charrow | P. Maison-Blanche | H. Baris | M. Balwani | P. Mistry | A. El‐Beshlawy | P. Kishnani | T. Cox | T. Burrow | S. Danda | G. Pastores | H. Rosenbaum | B. Rosenbloom | Selena Freisens | G. Drelichman | G. Cox | E. Hadjiev | E. Lukina | C. Fraga | M. Petakov | A. Martins | M. Dragosky | H. B. Turkia | L. Underhill | Sebastiaan J. M. Gaemers | M. J. Peterschmitt | Cristina Fraga
[1] M. Foster,et al. Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1 , 2018, Orphanet Journal of Rare Diseases.
[2] D. Barbouth,et al. Causes of death in 184 patients with type 1 Gaucher disease from the United States who were never treated with enzyme replacement therapy. , 2018, Blood cells, molecules & diseases.
[3] Yuyu Feng,et al. Clinical and molecular characteristics of patients with Gaucher disease in Southern China. , 2018, Blood cells, molecules & diseases.
[4] J. Ibrahim,et al. A pooled analysis of adverse events in 393 adults with Gaucher disease type 1 from four clinical trials of oral eliglustat: Evaluation of frequency, timing, and duration. , 2018, Blood cells, molecules & diseases.
[5] J. Szer,et al. Should eliglustat be first line therapy for patients with type 1 Gaucher disease? Definitions of safety and efficacy. , 2018, Blood cells, molecules & diseases.
[6] P. Mistry,et al. Therapeutic position of eliglustat. , 2017, Blood cells, molecules & diseases.
[7] S. Packman,et al. Outcomes after 18 months of eliglustat therapy in treatment‐naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trial , 2017, American journal of hematology.
[8] M. Pedroso,et al. Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy. , 2017, Blood.
[9] J. Ibrahim,et al. Clinical response to eliglustat in treatment-naïve patients with Gaucher disease type 1: Post-hoc comparison to imiglucerase-treated patients enrolled in the International Collaborative Gaucher Group Gaucher Registry , 2016, Molecular genetics and metabolism reports.
[10] J. Fletcher,et al. Interruption of enzyme replacement therapy in Gaucher disease. , 2016, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.
[11] M. Balwani,et al. Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial , 2015, The Lancet.
[12] J. Stirnemann,et al. Impact of imiglucerase supply constraint on the therapeutic management and course of disease in French patients with Gaucher disease type 1 , 2015, Orphanet Journal of Rare Diseases.
[13] S. Packman,et al. Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial. , 2015, JAMA.
[14] Pilar Giraldo,et al. A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase. , 2014, Blood cells, molecules & diseases.
[15] P. Svenningsson,et al. Impact of Imiglucerase Supply Shortage on Clinical and Laboratory Parameters in Norrbottnian Patients with Gaucher Disease Type 3 , 2014, Archivum Immunologiae et Therapiae Experimentalis.
[16] J J Swen,et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants , 2013, Clinical pharmacology and therapy.
[17] Laurie D. Smith,et al. Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase , 2013, American journal of hematology.
[18] A. Mehta,et al. Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. , 2011, Blood.
[19] D. Elstein,et al. Nonprecipitous changes upon withdrawal from imiglucerase for Gaucher disease because of a shortage in supply. , 2011, Blood cells, molecules & diseases.
[20] J. Fletcher,et al. Enzyme replacement therapy "drug holiday": results from an unexpected shortage of an orphan drug supply in Australia. , 2011, Blood cells, molecules & diseases.
[21] P. Bonate,et al. A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. , 2010, Blood.
[22] B. Bembi,et al. Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease. , 2010, Blood cells, molecules & diseases.
[23] Y. Eto,et al. Clinical and genetic study of Japanese patients with type 3 Gaucher disease. , 2009, Molecular genetics and metabolism.
[24] P. Kaplan,et al. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1. , 2009, Molecular genetics and metabolism.
[25] P. Mistry,et al. Life expectancy in Gaucher disease type 1 , 2008, American journal of hematology.
[26] S. Packman,et al. Phenotypic heterogeneity of N370S homozygotes with type I Gaucher disease: An analysis of 798 patients from the ICGG Gaucher Registry , 2008, Journal of Inherited Metabolic Disease.
[27] S. van Weely,et al. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. , 2007, Blood.
[28] S. Packman,et al. Imiglucerase (Cerezyme®) improves quality of life in patients with skeletal manifestations of Gaucher disease , 2007, Clinical genetics.
[29] V. Solano,et al. Quality of life related to type 1 Gaucher disease: Spanish experience , 2005, Quality of Life Research.
[30] G. Andria,et al. Therapeutic goals in the treatment of Gaucher disease. , 2004, Seminars in hematology.
[31] P. Kaplan,et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. , 2002, The American journal of medicine.
[32] R. Dwek,et al. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis , 2000, The Lancet.
[33] K. Sims,et al. Quality of life assessment in adults with type 1 Gaucher disease , 1999, Quality of Life Research.
[34] A. Damiano,et al. The health-related quality of life of adults with Gaucher's disease receiving enzyme replacement therapy: results from a retrospective study , 1998, Quality of Life Research.
[35] J. Dambrosia,et al. Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease. , 1991, The New England journal of medicine.
[36] J. Ibrahim,et al. Two-year postmarketing safety experience with oral eliglustat in adults with type 1 Gaucher disease , 2017 .
[37] B. Bembi,et al. Did the temporary shortage in supply of imiglucerase have clinical consequences? Retrospective observational study on 34 italian Gaucher type I patients. , 2013, JIMD reports.
[38] G. Grabowski,et al. Phenotypic and genotypic heterogeneity in Gaucher disease type 1: a comparison between Brazil and the rest of the world. , 2007, Molecular genetics and metabolism.
[39] R. Schiffmann,et al. Enzyme Therapy in Type 1 Gaucher Disease: Comparative Efficacy of Mannose-Terminated Glucocerebrosidase from Natural and Recombinant Sources , 1995, Annals of Internal Medicine.